PENTIXAPHARM

INVESTOR PRESENTATION

Highly concentrated version

Confidential

FALL 2023

1

Disclaimer

THIS COMMUNICATION CONTAINS STATEMENTS THAT CONSTITUTE 'FORWARD-LOOKING' STATEMENTS. FORWARD-LOOKING STATEMENTS INCLUDE, BUT ARE NOT LIMITED TO, STATEMENTS REGARDING OUR PLANS, OBJECTIVES, INTENTIONS, BELIEFS, EXPECTATIONS AND ASSUMPTIONS OR FUTURE EVENTS, PERFORMANCE OR RESULTS OF PERFORMANCE, AS WELL AS OTHER STATEMENTS THAT ARE NOT NECESSARILY HISTORICAL FACTS. YOU ARE CAUTIONED THAT THESE FORWARD-LOOKING STATEMENTS ARE ONLY PREDICTIONS AND ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND INVOLVE RISKS AND UNCERTAINTIES. OUR ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE DESCRIBED IN OUR FORWARD- LOOKING STATEMENTS DUE TO VARIOUS FACTORS, INCLUDING RESEARCH AND DEVELOPMENT PROGRESS AND OUTCOMES, COMPETITION, MARKET FACTORS, GENERAL ECONOMIC CONDITIONS AND OTHER FACTORS DESCRIBED ABOVE. WE DO NOT INTEND TO UPDATE OR REVISE ANY FORWARD-LOOKING STATEMENTS, WHETHER BECAUSE OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

THIS COMMUNICATION CONTAINS MARKET DATA RELATED TO OUR BUSINESS AND INDUSTRY. SUCH MARKET DATA INCLUDES PROJECTIONS THAT ARE BASED ON A NUMBER OF ASSUMPTIONS. IF ANY OF OUR ASSUMPTIONS PROVE TO BE INCORRECT, OUR ACTUAL RESULTS MAY SIGNIFICANTLY DIFFER FROM OUR PROJECTIONS BASED ON THESE ASSUMPTIONS. THE ASSUMPTIONS WE HAVE USED IN MAKING THESE STATEMENTS ARE THOSE WE BELIEVE ARE REASONABLE AND MOST SIGNIFICANT TO THE PROJECTIONS AS OF THE DATE OF THIS COMMUNICATION. TO THE EXTENT THAT OUR ASSUMPTIONS AND OTHER ASSUMED EVENTS DO NOT MATERIALIZE, OUR ACTUAL RESULTS MAY VARY SUBSTANTIALLY FROM THE PROJECTED OPERATING AND FINANCIAL INFORMATION, INCLUDING OUR PROJECTED FINANCIAL STATEMENTS, PERFORMANCE OR RESULTS, CONTAINED IN THIS COMMUNICATION.

2

To harvest the full potential

of CXCR4

EZAG seeks co-investors

Act as

Provide

Focus on

Assist in IPO

Provide know-

Technically a

sparring-

clinical

value

preparation

how in

"Series B"

partners to

development

creation

business

Investment

EZAG and

know-how

development

PentixaPharm

team

3

What Does PTX Offer?

  • Significant short-term revenue generation through late-stage,therapy-enablingGa68-CXCR4
    • Phase-III-readyfor marginal zone lymphoma in Europe
    • Phase-III-readinesspending for hypertension in US

Use of Ga-68-CXCR4 for HYPERTENSION represent a first-in-class medical breakthrough

  • World class clinical pipeline targeting billion-dollar markets
    • Rheumatoid Arthritis with TAM > 7 billion USD
    • Recurrent Epithelial Ovarian Cancer with TAM > 5 billion USD
    • Myelomas and leukaemia as promising next therapy areas
    • 2nd generation, value-adding diagnostics for hypertension, haemato-oncology and muscle invading bladder cancer.
  • A theragnostic play outside the overfunded PSMA/ NET crowd
    • Abundant clinical evidence
    • established supply chains
    • Experienced entrepreneurial team with proven track record

4

Needed for Cash Break-Even: 65 M€

Deployable for pipeline: 250 M€

The quick way to sales revenues and financial self-sustainability

PRIMARY

HYPERALDOSTERONISM

6

Primary Aldosteronism is a Major Cause of Hypertension

7

https://www.diasorin.com/sites/default/files/allegati_prodotti/ese_spin_brochure_rev._03_low.pdf

Cumbersome Diagnostics Prevent Million of Treatments

8

Main Challenge/ Bottleneck:

Adrenal Venous Sampling

Complicated, CT guided vein sampling

Adrenal Venous Sampling:

  • Essential for distinguishing unilateral (curable) from bilateral (uncurable) cases.
  • Extremely challenging technical procedure
  • Succes rates vary between 8 and 61%
  • Low sensitivity (high rate of false positives)
  • Low specificity (reason for gradient vary)

Pentixapharms PET-Scan will

Eliminate the Bottleneck

Favourable Health Economics and Outcome Research (HEOR)

  • Ga-68-CXCRmore specific and more sensitive than AVS
    • Based on current IIS clinical data
  • Cost advantage of Ga-68-CXCR over AVS > 15,000 USD per patient
    • Surgical procedure substituted with a PET-scan
    • Income loss to surgeons from AVS decline likely compensated by larger volume of adrenalectomies
  • Significant OSHA advantages of Ga-68-CXCR over AVS
    • Eliminates radiation exposure (from CT) for surgeons
  • In proportion, Ga-68-CXCR4 to benefit African-Americans more1
    • Relevant for reimbursement/ FIND Act

10

1REasons for Geographic And Racial Differences in Stroke (REGARDS) study

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Eckert & Ziegler AG published this content on 26 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 November 2023 15:40:29 UTC.